Research Roundup: Psychology Of Teenagers; UTIs; Drug Compounders
Each week, KHN compiles a selection of recently released health policy studies and briefs.
ScienceDaily:
Early Signs: Perceptual Distortions In Late-Teens Predict Psychotic Symptoms In Mid-Life
Schizophrenia is often diagnosed well into adulthood, typically from the late teens to early 40s. Are there early indicators that could help predict which individuals will go on to develop this serious mental illness? Researchers in clinical psychology and psychiatry have long sought to answer this question. New research by Distinguished Professor Mark F. Lenzenweger at Binghamton University and Weill Cornell Medical College could point the way. (Binghamton University, 7/27)
American Academy Of Pediatrics:
Depression And Suicide-Risk Screening Results In Pediatric Primary Care
Depression is common, and suicide rates are increasing. Adolescent depression screening might miss those with unidentified suicide risk. Our primary objective in this study was to compare the magnitude of positive screen results across different approaches. (Kemper et al, 7/1)
American Academy Of Pediatrics:
Progression Of Gender Dysphoria In Children And Adolescents: A Longitudinal Study
This study characterized the progression of GD behavior in children and adolescents. Less than one-third of GD youth receive an eventual GDRD, and approximately one-quarter receive GAHT. Female sex at birth, older age of initial GD presentation to medical care, and non-Hispanic white race and ethnicity increased the likelihood of receiving diagnosis and treatment. (Wagner et al, 7/1)
In pharmaceutical news —
CIDRAP:
FDA Rejects New Drug Application For Sulopenem
Pharmaceutical company Iterum Therapeutics said yesterday that the US Food and Drug Administration (FDA) has rejected the company's new drug application (NDA) for approval of its oral antibiotic sulopenem etzadroxil/probenecid.Iterum is seeking approval of the antibiotic for treatment of uncomplicated urinary tract infections (UTIs) in patients who do not do not respond to treatment with fluoroquinolones. But in a Jul 23 Complete Response Letter (CRL) to the company, the FDA said it could not approve the NDA in its current form. (7/27)
CIDRAP:
Drug Compounding Helped Address Drug Gaps During COVID
As drug demand surged during the early months of the pandemic, the US Food and Drug Administration (FDA) published temporary guidelines to free up a pharmaceutical drug source that seemed much more domestic: drug compounders, or specific pharmacies and outsourcing facilities that make specialized drug formulations. So to what extent can drug compounding help with shortages? Or, is the very question indicative of a bigger problem? (McLernon, 7/27)
